Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528619 · ClinicalTrials.gov registry record · Phase 1
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT00528619 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 96 participants.
The verdict
NCT00528619, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
Interventions
- DRUG Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528619
The ClinicalTrials.gov registry entry for NCT00528619 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sunitinib, Pemetrexed, Cisplatin, Carboplatin is the first listed.
NCT00528619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528619 about?
NCT00528619 is a clinical study titled "A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors". This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
What is the current status of trial NCT00528619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2006-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00528619?
The interventions under investigation include: Sunitinib, Pemetrexed, Cisplatin, Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00528619?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.